Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) CEO Sells 80,388 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 80,388 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $67.53, for a total value of $5,428,601.64. Following the sale, the chief executive officer now owns 5,293,005 shares in the company, valued at approximately $357,436,627.65. This trade represents a 1.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Tempus AI Stock Up 6.1 %

Shares of TEM opened at $68.96 on Friday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The company’s 50-day moving average is $44.36 and its 200-day moving average is $48.84.

Hedge Funds Weigh In On Tempus AI

Institutional investors and hedge funds have recently made changes to their positions in the company. Vestmark Advisory Solutions Inc. raised its stake in Tempus AI by 148.3% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 122,450 shares of the company’s stock worth $4,134,000 after purchasing an additional 73,132 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Tempus AI during the 4th quarter worth approximately $3,757,000. Victory Capital Management Inc. acquired a new stake in shares of Tempus AI during the 4th quarter worth approximately $216,000. SBI Securities Co. Ltd. bought a new position in Tempus AI in the fourth quarter valued at approximately $673,000. Finally, US Bancorp DE acquired a new position in Tempus AI during the fourth quarter valued at approximately $80,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and raised their price objective for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Needham & Company LLC restated a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a report on Tuesday, January 14th. Guggenheim started coverage on shares of Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 price objective for the company. Wolfe Research assumed coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Finally, Loop Capital lowered their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $58.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.